JP6347793B2 - Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法 - Google Patents
Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法 Download PDFInfo
- Publication number
- JP6347793B2 JP6347793B2 JP2015553788A JP2015553788A JP6347793B2 JP 6347793 B2 JP6347793 B2 JP 6347793B2 JP 2015553788 A JP2015553788 A JP 2015553788A JP 2015553788 A JP2015553788 A JP 2015553788A JP 6347793 B2 JP6347793 B2 JP 6347793B2
- Authority
- JP
- Japan
- Prior art keywords
- bcl
- compound
- alkyl
- cancer
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753066P | 2013-01-16 | 2013-01-16 | |
| US61/753,066 | 2013-01-16 | ||
| PCT/US2014/011571 WO2014113413A1 (en) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506916A JP2016506916A (ja) | 2016-03-07 |
| JP2016506916A5 JP2016506916A5 (OSRAM) | 2017-01-26 |
| JP6347793B2 true JP6347793B2 (ja) | 2018-06-27 |
Family
ID=51165292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553788A Active JP6347793B2 (ja) | 2013-01-16 | 2014-01-15 | Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9096625B2 (OSRAM) |
| EP (2) | EP2945940B1 (OSRAM) |
| JP (1) | JP6347793B2 (OSRAM) |
| KR (2) | KR102318204B1 (OSRAM) |
| CN (3) | CN105246882A (OSRAM) |
| AU (1) | AU2014207716B2 (OSRAM) |
| CA (1) | CA2897055C (OSRAM) |
| ES (1) | ES2819232T3 (OSRAM) |
| HK (1) | HK1219734A1 (OSRAM) |
| NZ (1) | NZ709635A (OSRAM) |
| SG (1) | SG11201505525UA (OSRAM) |
| WO (1) | WO2014113413A1 (OSRAM) |
| ZA (1) | ZA201504902B (OSRAM) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105246882A (zh) * | 2013-01-16 | 2016-01-13 | 密执安大学评议会 | BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法 |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| EP3139942B1 (en) | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| AU2015292710A1 (en) | 2014-07-22 | 2017-02-16 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| CA2981753A1 (en) * | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| US11111259B2 (en) | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| WO2017172826A1 (en) | 2016-03-28 | 2017-10-05 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
| KR102447884B1 (ko) * | 2016-04-21 | 2022-09-27 | 바이오벤처스, 엘엘씨 | 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도 |
| CN106177955B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| WO2018098534A1 (en) * | 2016-12-02 | 2018-06-07 | Garvan Institute Of Medical Research | Methods of treating cancer and reagents thereof |
| US20200354336A9 (en) * | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| WO2019033122A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| AU2018314280B2 (en) * | 2017-08-11 | 2023-07-20 | Rsem, Société En Commandite | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| WO2019133988A1 (en) | 2017-12-30 | 2019-07-04 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| AU2019207616A1 (en) | 2018-01-10 | 2020-07-09 | Recurium Ip Holdings, Llc | Benzamide compounds |
| JP7385284B2 (ja) * | 2018-01-22 | 2023-11-22 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー | 癌処置のためのｂｃｌ－２タンパク質分解剤 |
| SI3788042T1 (sl) | 2018-04-29 | 2025-06-30 | Beigene Switzerland Gmbh | Zaviralci BCL-2 |
| US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CN117866015A (zh) | 2018-04-30 | 2024-04-12 | 联合生物科技公司 | 一种临床管理中使用的化合物及其用途 |
| CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2019221755A1 (en) | 2018-05-18 | 2019-11-21 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US11491168B2 (en) | 2018-07-31 | 2022-11-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof |
| AU2019315466B2 (en) | 2018-07-31 | 2022-05-19 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
| EP3672594B1 (en) | 2018-07-31 | 2021-09-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| TW202019421A (zh) * | 2018-07-31 | 2020-06-01 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2/Bcl-xL抑制劑與化療藥物的組合及其應用 |
| TWI725488B (zh) | 2018-07-31 | 2021-04-21 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途 |
| CN114522167A (zh) * | 2018-07-31 | 2022-05-24 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| WO2020041405A1 (en) | 2018-08-22 | 2020-02-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US11872237B2 (en) | 2018-12-28 | 2024-01-16 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and preparation method thereof |
| TWI729662B (zh) * | 2019-01-04 | 2021-06-01 | 大陸商蘇州亞盛藥業有限公司 | 一種磺胺類化合物及製備磺胺類化合物的製程 |
| EP3906235B1 (en) * | 2019-01-04 | 2023-03-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing sulfonamides drugs |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| TW202114692A (zh) * | 2019-07-02 | 2021-04-16 | 大陸商蘇州亞盛藥業有限公司 | 一種含有mTOR抑制劑的藥物組合及其應用 |
| WO2021018240A1 (en) * | 2019-07-31 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of a bcl-2/bcl-xl inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021078301A1 (zh) * | 2019-10-24 | 2021-04-29 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| TWI885019B (zh) * | 2019-11-27 | 2025-06-01 | 大陸商蘇州亞盛藥業有限公司 | 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物 |
| EP4069233A4 (en) * | 2019-12-04 | 2024-03-13 | Ascentage Pharma (Suzhou) Co., Ltd. | PHARMACEUTICAL COMBINATION AND USE THEREOF |
| US20230025865A1 (en) * | 2019-12-11 | 2023-01-26 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS |
| CN113350281B (zh) * | 2020-03-02 | 2023-08-15 | 苏州亚盛药业有限公司 | 载药聚合物胶束及其制剂和制备方法 |
| US20220296557A1 (en) * | 2020-04-10 | 2022-09-22 | Ascentage Pharma (Suzhou) Co., Ltd. | Combinations of bcl-2/bcl-xl inhibitors and related uses |
| WO2021208963A1 (en) | 2020-04-15 | 2021-10-21 | Beigene, Ltd. | Bcl-2 inhibitor |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| EP4175644A1 (en) | 2020-07-06 | 2023-05-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| WO2022012481A1 (en) * | 2020-07-13 | 2022-01-20 | Ascentage Pharma (Suzhou) Co., Ltd. | Crystalline or Amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts |
| CN114053288B (zh) * | 2020-07-31 | 2024-11-19 | 苏州亚盛药业有限公司 | 肺部疾病治疗的组合物和方法 |
| JP7688141B2 (ja) * | 2020-11-10 | 2025-06-03 | ユニティ バイオテクノロジー インコーポレイテッド | Ｂｃｌの結晶性固体メグルミン塩阻害物質、並びに前記阻害物質を作製及び使用する方法 |
| WO2022111647A1 (en) * | 2020-11-27 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof |
| US12454674B2 (en) | 2020-12-04 | 2025-10-28 | University Of Notre Dame Du Lac | Method of encapsulating single cells utilizing an alternating current electrospray |
| US20250099440A1 (en) * | 2021-08-02 | 2025-03-27 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical combination and use thereof |
| EP4565236A1 (en) * | 2022-08-02 | 2025-06-11 | Beijing Neox Biotech Limited | Bcl-xl degrading compounds |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| WO2024245312A1 (en) * | 2023-05-30 | 2024-12-05 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| KR20070046180A (ko) | 2004-08-20 | 2007-05-02 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 항세포사멸 ｂｃｌ-2군 구성원의 소분자 억제제 및 이의용도 |
| DK1888550T3 (da) | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| WO2007061923A2 (en) | 2005-11-18 | 2007-05-31 | Takeda San Diego, Inc. | Glucokinase activators |
| MX2009002422A (es) * | 2006-09-05 | 2009-03-20 | Abbott Lab | Inhibidores bcl para tratar exceso de plaquetas. |
| DK2324008T3 (da) | 2008-07-24 | 2012-07-23 | Nerviano Medical Sciences Srl | Diarylpyrazol som protein kinase inhibitorer |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| KR101762724B1 (ko) * | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| CN105246882A (zh) * | 2013-01-16 | 2016-01-13 | 密执安大学评议会 | BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法 |
-
2014
- 2014-01-15 CN CN201480015733.0A patent/CN105246882A/zh active Pending
- 2014-01-15 JP JP2015553788A patent/JP6347793B2/ja active Active
- 2014-01-15 AU AU2014207716A patent/AU2014207716B2/en active Active
- 2014-01-15 HK HK16107756.1A patent/HK1219734A1/zh unknown
- 2014-01-15 KR KR1020207037597A patent/KR102318204B1/ko active Active
- 2014-01-15 CN CN201910634723.XA patent/CN110305162A/zh active Pending
- 2014-01-15 NZ NZ70963514A patent/NZ709635A/en unknown
- 2014-01-15 US US14/155,809 patent/US9096625B2/en active Active
- 2014-01-15 SG SG11201505525UA patent/SG11201505525UA/en unknown
- 2014-01-15 ES ES14741180T patent/ES2819232T3/es active Active
- 2014-01-15 EP EP14741180.5A patent/EP2945940B1/en active Active
- 2014-01-15 CN CN201910634742.2A patent/CN110302205B/zh active Active
- 2014-01-15 WO PCT/US2014/011571 patent/WO2014113413A1/en not_active Ceased
- 2014-01-15 KR KR1020157021823A patent/KR102210316B1/ko active Active
- 2014-01-15 CA CA2897055A patent/CA2897055C/en active Active
- 2014-01-15 EP EP20163914.3A patent/EP3689886A1/en not_active Withdrawn
-
2015
- 2015-07-08 ZA ZA2015/04902A patent/ZA201504902B/en unknown
- 2015-08-03 US US14/816,191 patent/US9403856B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140199234A1 (en) | 2014-07-17 |
| KR20210002126A (ko) | 2021-01-06 |
| CN105246882A (zh) | 2016-01-13 |
| KR102318204B1 (ko) | 2021-10-26 |
| KR102210316B1 (ko) | 2021-01-29 |
| EP2945940A1 (en) | 2015-11-25 |
| US20150336994A1 (en) | 2015-11-26 |
| US9403856B2 (en) | 2016-08-02 |
| ZA201504902B (en) | 2016-07-27 |
| CN110305162A (zh) | 2019-10-08 |
| CA2897055A1 (en) | 2014-07-24 |
| EP2945940A4 (en) | 2016-07-06 |
| CN110302205B (zh) | 2020-06-09 |
| EP2945940B1 (en) | 2020-07-15 |
| HK1219734A1 (zh) | 2017-04-13 |
| ES2819232T3 (es) | 2021-04-15 |
| SG11201505525UA (en) | 2015-08-28 |
| CN110302205A (zh) | 2019-10-08 |
| WO2014113413A1 (en) | 2014-07-24 |
| EP3689886A1 (en) | 2020-08-05 |
| US9096625B2 (en) | 2015-08-04 |
| KR20150104631A (ko) | 2015-09-15 |
| CA2897055C (en) | 2021-04-20 |
| AU2014207716B2 (en) | 2017-07-27 |
| JP2016506916A (ja) | 2016-03-07 |
| NZ709635A (en) | 2019-10-25 |
| AU2014207716A1 (en) | 2015-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6347793B2 (ja) | Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法 | |
| JP5998152B2 (ja) | Ｂｃｌ−２／ｂｃｌ−ｘｌ阻害剤およびそれを使用する治療方法 | |
| JP6247298B2 (ja) | Ｉａｐタンパク質の二価阻害薬およびそれを用いた治療方法 | |
| AU2012209295A1 (en) | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same | |
| HK40025523A (en) | Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer | |
| HK40008278A (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same | |
| HK40008279B (en) | Medical use of bcl-2/bcl-xl inhibitors and pharmaceutical compositions thereof | |
| HK40008279A (en) | Medical use of bcl-2/bcl-xl inhibitors and pharmaceutical compositions thereof | |
| NZ613504B2 (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151113 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161209 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161209 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171026 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180131 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180507 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180522 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180529 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6347793 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |